US FDA Guidance On Patient Labeling Leaves Unanswered Questions For Combination Products
Final guidance does not address recommendations raised by PhRMA and others about product descriptions and incorporating human outcome factors in instructions for use.
You may also be interested in...
A new draft guidance document from the US agency offers nuts-and-bolts guidance on formatting Instructions for Use (IFUs) for drug-device and biologic-device combination product applications.
Chamber files petition to have FTC amend its disqualification rules to have commissioners explain their rejection of recusal requests. FTC is seeking public comments on the petition.
BIO objects to guidelines seeking to block mergers that would eliminate a potential entrant in a concentrated market and give greater scrutiny to transactions that are part of a series of company deals. APhA and NCPA call for FTC to consider more factors in PBM mergers.